A BILL FOR

1 An Act making changes to the controlled substance schedules,
2 and providing penalties.
3 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:
Section 1. Section 124.204, subsection 4, Code 2015, is amended by adding the following new paragraphs:

NEW PARAGRAPH. 4-methyl-N-ethylcathinone. Other names: 4-MEC, 2-(ethylamino)-1-(4-methylphenyl)propan-1-one.

NEW PARAGRAPH. 4-methyl-alpha-pyrrolidinopropiophenone. Other names: 4-MePPP, MePPP, 4-methyl-[alpha]-pyrrolidinopropiophenone, 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one.

NEW PARAGRAPH. Alpha-pyrrolidinopentiophenone. Other names: [alpha]-PVP, [alpha]-pyrrolidinovalerophenone, 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one.

NEW PARAGRAPH. Butylone. Other names: bk-MBDB, 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one.

names: [alpha]-methylaminovalerophenone, 2-(methylamino)-1-phenylpentan-1-one.

NEW PARAGRAPH. Pentedrone. Other names: [alpha]-methylaminovalerophenone, 2-(methylamino)-1-phenylpentan-1-one.

NEW PARAGRAPH. Pentylone. Other names: bk-MBDP, 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one.

Other names: 4-FMC, flephedrone, 1-(4-fluorophenyl)-2-(methylamino)propan-1-one.

NEW PARAGRAPH. 3-fluoro-N-methylcathinone. Other names: 3-FMC, 1-(3-fluorophenyl)-2-(methylamino)propan-1-one.

NEW PARAGRAPH. Naphyrone. Other names: naphthylpyrovalerone, 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one.

NEW PARAGRAPH. Alpha-pyrrolidinobutiophenone. Other names: [alpha]-PBP, 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one.

NEW PARAGRAPH. Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate. Other names: PB-22, QUPIC.

NEW PARAGRAPH. Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate. Other names: 5-fluoro-PB-22, 5F-PB-22.

NEW PARAGRAPH. N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-((4-fluorobenzyl)-1H-indazole-3-carboxamide. Other name:  
AB-FUBINACA.

NEW PARAGRAPH.  j.  N-(1-amino-3,3-dimethyl-1-oxobutan- 
2-yl)-1-pentyl-1H-indazole-3-carboxamide. Other name:  
ADB-PINACA.

Sec. 3. Section 124.208, subsection 5, paragraph a,  
subparagraphs (3) and (4), Code 2015, are amended by striking  
the subparagraphs.

Sec. 4. Section 124.210, subsection 2, Code 2015, is amended  
by adding the following new paragraph:

NEW PARAGRAPH.  c.  2-[(dimethylamino)methyl]-1- 
(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric  
isomers, and salts of these isomers (including tramadol).

Sec. 5. Section 124.210, subsection 3, Code 2015, is amended  
by adding the following new paragraphs:

NEW PARAGRAPH.  bb.  Alfaxalone.

NEW PARAGRAPH.  bc.  Suvorexant.

EXPLANATION  
The inclusion of this explanation does not constitute agreement with  
the explanation's substance by the members of the general assembly.

This bill modifies the controlled substance schedules, and  
provides penalties.

The bill adds 10 synthetic cathinones and four synthetic  
cannabinoids to the list of substances classified as schedule I  
controlled substances. The board of pharmacy has determined  
that these substances should be classified as schedule I  
controlled substances because each substance has a high  
potential for abuse and no accepted medical use in the United  
States.

The bill removes hydrocodone-combination products from  
the list of substances classified as schedule III controlled  
substances. Hydrocodone, as a single-entity substance,  
is currently classified as a schedule II controlled  
substance. The change under the bill effectively makes all  
hydrocodone-containing products subject to the controls,
security, reporting, and penalty provisions for schedule II
controlled substances.

The bill also classifies the substance commonly known as
tramadol, a centrally acting opioid analgesic, as a schedule
IV controlled substance. This substance was previously
marketed and distributed as a noncontrolled prescription
drug. Effective August 18, 2014, the federal Drug Enforcement
Administration classified tramadol as a schedule IV controlled
substance under federal law.

The bill also classifies alfaxalone, a neurosteroid with
central nervous system depressant properties, as a schedule IV
controlled substance. The federal Food and Drug Administration
recently approved this intravenous injectable anesthetic for
use by or on the order of a licensed veterinarian. Alfaxalone
is not available by prescription and is approved for use in
veterinary practice.

The bill classifies suvorexant, a new insomnia treatment
approved by the federal Food and Drug Administration,
as a schedule IV controlled substance. This is a novel,
first-in-class chemical substance and information on actual
abuse data is not available. However, data from clinical
studies supports the classification in schedule IV.

It is a class "C" felony pursuant to Code section
124.401(1)(c)(8) for any unauthorized person to violate a
provision of Code section 124.401 involving a classified
substance placed on schedule I, II, or III pursuant to the
bill. A class "C" felony for this particular offense is
punishable by confinement for no more than 10 years and a fine
of at least $1,000 but not more than $50,000.

It is an aggravated misdemeanor pursuant to Code section
124.401(1)(d) for any unauthorized person to violate a
provision of Code section 124.401 involving a classified
substance placed on schedule IV pursuant to the bill. An
aggravated misdemeanor is punishable by confinement for no more
than two years and a fine of at least $625 but not more than
$6,250.

If a person possesses a controlled substance in violation of Code section 124.401(5) as a first offense, the person commits a serious misdemeanor. A serious misdemeanor is punishable by confinement for no more than one year and a fine of at least $315 but not more than $1,875.